# Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases

> **NCT00081159** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 80 (actual)

## Conditions studied

- Metastatic Cancer
- Prostate Cancer

## Interventions

- **DRUG:** Doxorubicin hydrochloride
- **DRUG:** Goserelin acetate
- **DRUG:** Leuprolide acetate
- **DRUG:** Zoledronic acid
- **PROCEDURE:** orchiectomy
- **RADIATION:** strontium chloride Sr

## Key facts

- **NCT ID:** NCT00081159
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2016-11-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00081159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00081159, "Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00081159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*